COMMUNIQUÉS West-GlobeNewswire

Brain Based Health Solutions’ Dr. Clint Steele Releases “101 Brain Hacks” to Rewrite the Future of Dementia Prevention and Even Reversal
16/12/2025
Portland, Maine, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Most people believe dementia is a life sentence. Dr. Clint Steele once believed that, too, until a moment in his practice changed everything. Today, the #1 best-selling [...]
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
15/12/2025
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Kyverna Therapeutics Announces Proposed Public Offering of Common Stock
15/12/2025
EMERYVILLE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune [...]
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
15/12/2025
Conference call and webcast to be held at 8 a.m. ET on December 16, 2025 BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel [...]
IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications
15/12/2025
Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic melanoma Five-year analysis of median progression free survival was 25.5 months [...]
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
15/12/2025
CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on Monday, January 12 [...]
AEON Biopharma Announces Execution of Exchange Agreement with Daewoong
15/12/2025
- AEON and Daewoong Pharmaceutical have executed definitive documentation to exchange $15 million of notes plus accrued interest into new equity, $1.5 million of new notes due 2030, and a cash-exercise warrant for 8 [...]
Abivax Presents Third Quarter 2025 Financial Results
15/12/2025
Abivax Presents Third Quarter 2025 Financial Results Cash and cash equivalents of EUR 589.7 (as of September 30, 2025) with a cash runway into Q4 2027 PARIS, France, December 15, 2025, 10:05 p.m. CET – Abivax SA ( [...]
HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
15/12/2025
Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” [...]
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15/12/2025
AUSTIN, TX and DURHAM, NC, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics [...]
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
15/12/2025
Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative [...]
BioSyent Announces Renewal of Normal Course Issuer Bid
15/12/2025
MISSISSAUGA, Ontario, Dec. 15, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of [...]
Cellectis annonce la décision du tribunal arbitral dans le litige l’opposant à Servier
15/12/2025
NEW YORK, 15 déc. 2025 (GLOBE NEWSWIRE) -- Cellectis (la « Société ») (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome pour [...]
Cellectis Announces Arbitral Decision in Dispute with Servier
15/12/2025
NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
XOMA Royalty Enters into Agreement to Acquire Generation Bio
15/12/2025
- Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna - - Generation Bio’s cell-targeted lipid nanoparticles (ctLNP) delivery platform for [...]
Vivos Therapeutics to Participate in Online Fireside Chat with Water Tower Research on December 16, 2025, at 11 am EST
15/12/2025
LITTLETON, Colo., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the delivery of highly [...]
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
15/12/2025
Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the [...]
Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones
15/12/2025
Holders will have until December 30, 2025 to exercise Tranche A Warrants at $1.05 per share, enabling up to $17.9 million in potential gross proceeds BURLINGTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, [...]
AB Science annonce une nouvelle publication sur biorxiv identifiant AB8939 comme un candidat médicament prometteur pour le traitement de la leucémie myéloïde aiguë réfractaire et potentiellement d'autres cancers
15/12/2025
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE UNE NOUVELLE PUBLICATION SUR BIORXIV QUI IDENTIFIE ET CARACTÉRISE UNE NOUVELLE MOLÉCULE SYNTHÉTIQUE, AB8939, COMME UN CANDIDAT MÉDICAMENT PROMETTEUR POUR LE TRAITEMENT DE LA [...]

Pages